Seeking Alpha

Biogen Idec (BIIB -0.2%) and Elan (ELN -0.5%) submit applications to the FDA and EMA requesting...

Biogen Idec (BIIB -0.2%) and Elan (ELN -0.5%) submit applications to the FDA and EMA requesting labeling updates to Tysabri to expand the indication to include first-line use for people living with relapsing forms of multiple sclerosis who have tested negative for antibodies to the JC virus. If approved, it will allow all anti-JCV antibody negative patients to consider the drug early in the course of treatment, regardless of the level of disease activity or prior treatment history.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)